Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date28 Aug 2019 |
A phase III, Randomized, Open label, Controlled, Multicentre, Clinical study of the Safety and Efficacy of Toppically Applied Moist Exposed Burn Ointment (MEBO) Compared to Silver Sulphadiazine (SSD) in subjects with Mild thermal burn injuries.
100 Clinical Results associated with Shantou Mebo Pharmaceutical Co. Ltd.
0 Patents (Medical) associated with Shantou Mebo Pharmaceutical Co. Ltd.
100 Deals associated with Shantou Mebo Pharmaceutical Co. Ltd.
100 Translational Medicine associated with Shantou Mebo Pharmaceutical Co. Ltd.